Skip to main content
SpringerLink
Log in

Central Nervous System Tumors

  • Chapter
Oncology

Abstract

The term primary central nervous system tumors refers to a heterogeneous group of tumors characterized by their location in the central nervous system (CNS). These tumors exhibit a wide range of clinical behavior from extremely lethal (e.g., glioblastoma) to potentially curable (e.g., germ cell tumors and medulloblastomas). The occurrence of these tumors has devastating effects on patients, and their management can be major challenge to physicians. By virtue of their location, brain tumors cause a disproportionate amount of disability and pose a threat to a patient’s sense of self that is unparalleled by any other disease. The currently available therapies for most primary CNS tumors have limited activity with significant toxicity. Survivors of these tumors often have significant residual neurologic and cognitive deficits that limit their functioning for the rest of their lives.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Greig NH, Ries LG, Yancik R, Rapoport SI. Increasing annual incidence of primary malignant brain tumors in the elderly. J Natl Cancer Inst 1990;82(20):1621–1624.

    Article  PubMed  CAS  Google Scholar 

  2. Curran WJ Jr. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704–710.

    Article  PubMed  Google Scholar 

  3. Shaw EG, Seiferheld W, Scott C, et al. Reexamining the Radiation Therapy Oncology Group (RTOG) Recursive Partitioning Analysis (RPA) for Glioblastoma Multiforme (GBM) patients. Proceedings, Annual ASTRO Meeting. Int J Radiat Oncol Biol Phys 2003;57(2):S135–S136.

    Google Scholar 

  4. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994;12(10):2013–2021.

    PubMed  CAS  Google Scholar 

  5. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001;7(4):839–845.

    PubMed  CAS  Google Scholar 

  6. Fuller GN, Hess KR, Rhee CH, et al. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol 2002;12(1):108–116.

    Article  PubMed  CAS  Google Scholar 

  7. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (Lond) 2002;415(6870):436–442.

    Article  CAS  Google Scholar 

  8. Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology 1993;43(9):1678–1683.

    PubMed  CAS  Google Scholar 

  9. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54(10):1886–1893.

    PubMed  CAS  Google Scholar 

  10. Sugahara T, Korogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000;21(5):901–909.

    PubMed  CAS  Google Scholar 

  11. Speck O, Thiel T, Hennig J. Grading and therapy monitoring of astrocytomas with 1H-spectroscopy: preliminary study. Anticancer Res 1996;16(3B):1581–1585.

    PubMed  CAS  Google Scholar 

  12. Gupta R, Sinha U, Cloughesy T, Alger J. Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. Magn Reson Med 1999;41(1):2–7.

    Article  PubMed  CAS  Google Scholar 

  13. Quevedo JF, Buckner JC, Schmidt JL, Dinapoli RP, O’Fallon JR. Thromboembolism in patients with high-grade glioma. Mayo Clin Proc 1994;69(4):329–332.

    PubMed  CAS  Google Scholar 

  14. Streiff MB, Weir EG, Kickler TS, Htut M, Grossman SA. ABO blood group is a risk factor for venous thromboembolism in patients with malignant gliomas. Proc Am Soc Clin Oncol 2003;22:113.

    Google Scholar 

  15. Silber JH, Radcliffe J, Peckham V, et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J Clin Oncol 1992;10(9):1390–1396.

    PubMed  CAS  Google Scholar 

  16. Chin HW, Maruyama Y. Age at treatment and long-term performance results in medulloblastoma. Cancer (Phila) 1984;53(9):1952–1958.

    Article  PubMed  CAS  Google Scholar 

  17. Silverman CL, Palkes H, Talent B, Kovnar E, Clouse JW, Thomas PR. Late effects of radiotherapy on patients with cerebellar medulloblastoma. Cancer (Phila) 1984;54(5):825–829.

    Article  PubMed  CAS  Google Scholar 

  18. Catania MA, Marciano MC, Parisi A, et al. Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils. Eur J Pharmacol 2002;437(3):147–150.

    Article  PubMed  CAS  Google Scholar 

  19. Fike JR, Gobbel GT, Marton LJ, Seilhan TM. Radiation brain injury is reduced by the polyamine inhibitor alpha-difluoromethylornithine. Radiat Res 1994;138(1):99–106.

    Article  PubMed  CAS  Google Scholar 

  20. Kondziolka D, Mori Y, Martinez AJ, McLaughlin MR, Flickinger JC, Lunsford LD. Beneficial effects of the radioprotectant 21-aminosteroid U-74389G in a radiosurgery rat malignant glioma model. Int J Radiat Oncol Biol Phys 1999;44(1):179–184.

    Article  PubMed  CAS  Google Scholar 

  21. Weitzner MA, Meyers CA, Valentine AD. Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci 1995;7(3):347–350.

    PubMed  CAS  Google Scholar 

  22. Plafki C, Carl UM, Glag M, Hartmann KA. The treatment of late radiation effects with hyperbaric oxygenation (HBO). Strahlenther Onkol 1998;174(suppl 3):66–68.

    PubMed  Google Scholar 

  23. Surma-aho O, Niemela M, Vilkki J, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 2001;56(10):1285–1290.

    PubMed  CAS  Google Scholar 

  24. Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer 1998;34(12):1902–1909.

    Article  PubMed  CAS  Google Scholar 

  25. Hochberg FH, Slotnick B. Neuropsychologic impairment in astrocytoma survivors. Neurology 1980;30(2):172–177.

    PubMed  CAS  Google Scholar 

  26. Torres IJ, Mundt AJ, Sweeney PJ, et al. A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors. Neurology 2003;60(7):1113–1118.

    PubMed  CAS  Google Scholar 

  27. Taylor BV, Buckner JC, Cascino TL, et al. Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. J Clin Oncol 1998;16(6):2195–2201.

    PubMed  CAS  Google Scholar 

  28. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003;99(3):467–473.

    PubMed  Google Scholar 

  29. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303(23):1323–1329.

    Article  PubMed  CAS  Google Scholar 

  30. Laperriere N, Zuraw L, Cairncross G. The Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002;64(3):259–273.

    Article  PubMed  Google Scholar 

  31. Shapiro WR, Green SB, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 1989;71(1):1–9.

    PubMed  CAS  Google Scholar 

  32. Kita M, Okawa T, Tanaka M, Ikeda M. Radiotherapy of malignant glioma: prospective randomized clinical study of whole brain vs local irradiation. Gan No Rinsho (Japanese Journal of Cancer Clinics) 1989;35(11):1289–1294.

    CAS  Google Scholar 

  33. Bauman GS, Gaspar LE, Fisher BJ, Halperin EC, Macdonald DR, Cairncross JG. A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1994;29(4):835–839.

    PubMed  CAS  Google Scholar 

  34. Hoegler DB, Davey P. A prospective study of short course radiotherapy in elderly patients with malignant glioma. J Neuro-Oncol 1997;33(3):201–204.

    Article  CAS  Google Scholar 

  35. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer (Phila) 1993;71(8):2585–2597.

    Article  PubMed  CAS  Google Scholar 

  36. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359(9311):1011–1018.

    Article  PubMed  CAS  Google Scholar 

  37. Stupp R, Mason WP, Van Den Bent MJ, et al. Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT groups and NCIC Clinical Trials Group. Proc Am Soc Clin Oncol 2004;23:1 (abstract 2).

    Google Scholar 

  38. van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003;21(13):2525–2528.

    Article  PubMed  CAS  Google Scholar 

  39. Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001;19(9):2449–2455.

    PubMed  CAS  Google Scholar 

  40. Cairncross G, Seiferhel WS, E., Jenkins R, et al. An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: initial report of RTOG 94-02. Proc Am Soc Clin Oncol 2004;23:107 (abstract 1500).

    Google Scholar 

  41. Buckner JC, Brown LD, Kugler JW, et al. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg 1995;82(3):430–435.

    PubMed  CAS  Google Scholar 

  42. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17(9):2762–2771.

    PubMed  CAS  Google Scholar 

  43. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345(8956):1008–1012.

    Article  PubMed  CAS  Google Scholar 

  44. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 2003;5(2):79–88.

    Article  PubMed  CAS  Google Scholar 

  45. Shaw EG, Daumas-Duport C, Scheithauer BW, et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 1989;70(6):853–861.

    PubMed  CAS  Google Scholar 

  46. Lote K, Stenwig AE, Skullerud K, Hirschberg H. Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer 1998;34(1):98–102.

    Article  PubMed  CAS  Google Scholar 

  47. Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Ann Neurol 1992;31(4):431–436.

    Article  PubMed  CAS  Google Scholar 

  48. Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 2000;54(7):1442–1448.

    PubMed  CAS  Google Scholar 

  49. Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 2002;52(2):316–324.

    Article  PubMed  Google Scholar 

  50. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996;36(3):549–556.

    Article  PubMed  CAS  Google Scholar 

  51. Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997;86(5):747–754.

    PubMed  CAS  Google Scholar 

  52. Mahoney DH Jr, Cohen ME, Friedman HS, et al. Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro-Oncology 2000;2(4):213–220.

    Article  PubMed  Google Scholar 

  53. Massimino M, Spreafico F, Cefalo G, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol 2002;20(20):4209–4216.

    Article  PubMed  CAS  Google Scholar 

  54. Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 1993;11(5):850–856.

    PubMed  CAS  Google Scholar 

  55. Castello MA, Schiavetti A, Varrasso G, Clerico A, Cappelli C. Chemotherapy in low-grade astrocytoma management. Childs Nerv Syst 1998;14(1–2):6–9.

    Article  PubMed  CAS  Google Scholar 

  56. Buckner JC, Gesme D Jr, O’Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003;21(2):251–255.

    Article  PubMed  CAS  Google Scholar 

  57. Soffietti R, Ruda R, Bradac GB, Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998;43(5):1066–1073.

    Article  PubMed  CAS  Google Scholar 

  58. van den Bent MJ. New perspectives for the diagnosis and treatment of oligodendroglioma. Expert Rev Anticancer Ther 2001;1(3):348–356.

    Article  PubMed  Google Scholar 

  59. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003;21(4):646–651.

    Article  PubMed  CAS  Google Scholar 

  60. van den Bent MJ, Chinot O, Boogerd W, et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 2003;14(4):599–602.

    Article  PubMed  Google Scholar 

  61. Streffer J, Schabet M, Bamberg M, et al. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J Neurol 2000;247(4):297–302.

    Article  PubMed  CAS  Google Scholar 

  62. Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg 1993;78(6):909–914.

    PubMed  CAS  Google Scholar 

  63. Burkhard C, Di Patre PL, Schuler D, et al. A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg 2003;98(6):1170–1174.

    PubMed  Google Scholar 

  64. Giannini C, Scheithauer BW, Lopes MB, Hirose T, Kros JM, VandenBerg SR. Immunophenotype of pleomorphic xanthoastrocytoma. Am J Surg Pathol 2002;26(4):479–485.

    Article  PubMed  Google Scholar 

  65. Olivero WC, Lister JR, Elwood PW. The natural history and growth rate of asymptomatic meningiomas: a review of 60 patients. J Neurosurg 1995;83(2):222–224.

    PubMed  CAS  Google Scholar 

  66. Go RS, Taylor BV, Kimmel DW. The natural history of asymptomatic meningiomas in Olmsted County, Minnesota. Neurology 1998;51(6):1718–1720.

    PubMed  CAS  Google Scholar 

  67. Stafford SL, Perry A, Suman VJ, et al. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clinic Proc 1998;73(10):936–942.

    CAS  Google Scholar 

  68. Barbaro NM, Gutin PH, Wilson CB, Sheline GE, Boldrey EB, Wara WM. Radiation therapy in the treatment of partially resected meningiomas. Neurosurgery 1987;20(4):525–528.

    Article  PubMed  CAS  Google Scholar 

  69. Taylor BW Jr, Marcus RB Jr, Friedman WA, Ballinger WE Jr, Million RR. The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1988;15(2):299–304.

    Article  PubMed  Google Scholar 

  70. Hakim R, Alexander E III, Loeffler JS, et al. Results of linear accelerator-based radiosurgery for intracranial meningiomas. Neurosurgery 1998;42(3):446–453; discussion 53–54.

    Article  PubMed  CAS  Google Scholar 

  71. Petito CK, DeGirolami U, Earle KM. Craniopharyngiomas: a clinical and pathological review. Cancer (Phila) 1976;37(4):1944–1952.

    Article  PubMed  CAS  Google Scholar 

  72. Fahlbusch R, Honegger J, Paulus W, Huk W, Buchfelder M. Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg 1999;90(2):237–250.

    PubMed  CAS  Google Scholar 

  73. Kalapurakal JA, Goldman S, Hsieh YC, Tomita T, Marymont MH. Clinical outcome in children with craniopharyngioma treated with primary surgery and radiotherapy deferred until relapse. Med Pediatr Oncol 2003;40(4):214–218.

    Article  PubMed  Google Scholar 

  74. Merchant TE, Kiehna EN, Sanford RA, et al. Craniopharyngioma: the St. Jude Children’s Research Hospital experience 1984–2001. Int J Radiat Oncol Biol Phys 2002;53(3):533–542.

    Article  PubMed  Google Scholar 

  75. Prayson RA. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry. Ann Diagn Pathol 1999;3(1):11–18.

    Article  PubMed  CAS  Google Scholar 

  76. Healey EA, Barnes PD, Kupsky WJ, et al. The prognostic significance of postoperative residual tumor in ependymoma. Neurosurgery 1991;28(5):666–671; discussion 71–72.

    Article  PubMed  CAS  Google Scholar 

  77. Robertson PL, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children’s Cancer Group. J Neurosurg 1998;88(4):695–703.

    PubMed  CAS  Google Scholar 

  78. Evans AE, Anderson JR, Lefkowitz-Boudreaux IB, Finlay JL. Adjuvant chemotherapy of childhood posterior fossa ependymoma: cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: a Childrens Cancer Group study. Med Pediatr Oncol 1996;27(1):8–14.

    Article  PubMed  CAS  Google Scholar 

  79. Lyons MK, Kelly PJ. Posterior fossa ependymomas: report of 30 cases and review of the literature. Neurosurgery 1991;28(5): 659–664; discussion 64–65.

    Article  PubMed  CAS  Google Scholar 

  80. van Veelen-Vincent ML, Pierre-Kahn A, Kalifa C, et al. Ependymoma in childhood: prognostic factors, extent of surgery, and adjuvant therapy. J Neurosurg 2002;97(4):827–835.

    PubMed  Google Scholar 

  81. Ikezaki K, Matsushima T, Inoue T, Yokoyama N, Kaneko Y, Fukui M. Correlation of microanatomical localization with postoperative survival in posterior fossa ependymomas. Neurosurgery 1993;32(1):38–44.

    Article  PubMed  CAS  Google Scholar 

  82. Salazar OM. A better understanding of CNS seeding and a brighter outlook for postoperatively irradiated patients with ependymomas. Int J Radiat Oncol Biol Phys 1983;9(8):1231–1234.

    PubMed  CAS  Google Scholar 

  83. Goldwein JW, Leahy JM, Packer RJ, et al. Intracranial ependymomas in children. Int J Radiat Oncol Biol Phys 1990;19(6):1497–1502.

    PubMed  CAS  Google Scholar 

  84. Kovalic JJ, Flaris N, Grigsby PW, Pirkowski M, Simpson JR, Roth KA. Intracranial ependymoma long term outcome, patterns of failure. J Neuro-Oncol 1993;15(2):125–131.

    Article  CAS  Google Scholar 

  85. Rousseau P, Habrand JL, Sarrazin D, et al. Treatment of intracranial ependymomas of children: review of a 15-year experience. Int J Radiat Oncol Biol Phys 1994;28(2):381–386.

    PubMed  CAS  Google Scholar 

  86. Matsutani M, Sano K, Takakura K, et al. Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. J Neurosurg 1997;86(3):446–455.

    PubMed  CAS  Google Scholar 

  87. Schild SE, Haddock MG, Scheithauer BW, et al. Nongerminomatous germ cell tumors of the brain. Int J Radiat Oncol Biol Phys 1996;36(3):557–563.

    Article  PubMed  CAS  Google Scholar 

  88. Shirato H, Nishio M, Sawamura Y, et al. Analysis of long-term treatment of intracranial germinoma. Int J Radiat Oncol Biol Phys 1997;37(3):511–515.

    Article  PubMed  CAS  Google Scholar 

  89. Allen JC, Nisselbaum J, Epstein F, Rosen G, Schwartz MK. Alpha fetoprotein and human chorionic gonadotropin determination in cerebrospinal fluid. An aid to the diagnosis and management of intracranial germ-cell tumors. J Neurosurg 1979;51(3):368–374.

    PubMed  CAS  Google Scholar 

  90. Allen JC, DaRosso RC, Donahue B, Nirenberg A. A phase II trial of preirradiation carboplatin in newly diagnosed germinoma of the central nervous system. Cancer (Phila) 1994;74(3):940–944.

    Article  PubMed  CAS  Google Scholar 

  91. Calaminus G, Bamberg M, Baranzelli MC, et al. Intracranial germ cell tumors: a comprehensive update of the European data. Neuropediatrics 1994;25(1):26–32.

    Article  PubMed  CAS  Google Scholar 

  92. Matsutani M, Sano K, Takakura K, Fujimaki T, Nakamura O. Combined treatment with chemotherapy and radiation therapy for intracranial germ cell tumors. Childs Nerv Syst 1998;14(1–2):59–62.

    Article  PubMed  CAS  Google Scholar 

  93. Buckner JC, Peethambaram PP, Smithson WA, et al. Phase II trial of primary chemotherapy followed by reduced-dose radiation for CNS germ cell tumors. J Clin Oncol 1999;17(3):933–940.

    PubMed  CAS  Google Scholar 

  94. Tamayo P, Gaasenbeek M, Sturla LM, et al. Medulloblastoma: clinical presentation and management. Experience at the Hospital for Sick Children, Toronto, 1950–1980. J Neurosurg 1983;58(4):543–552.

    Google Scholar 

  95. Bourgouin PM, Tampieri D, Grahovac SZ, Leger C, Del Carpio R, Melancon D. CT and MR imaging findings in adults with cerebellar medulloblastoma: comparison with findings in children. AJR Am J Roentgenol 1992;159(3):609–612.

    PubMed  CAS  Google Scholar 

  96. Harisiadis L, Chang CH. Medulloblastoma in children: a correlation between staging and results of treatment. Int J Radiat Oncol Biol Phys 1977;2(9–10):833–841.

    PubMed  CAS  Google Scholar 

  97. del Charco JO, Bolek TW, McCollough WM, et al. Medulloblastoma: time-dose relationship based on a 30-year review. Int J Radiat Oncol Biol Phys 1998;42(1):147–154.

    Article  PubMed  Google Scholar 

  98. Raimondi AJ, Tomita T. Medulloblastoma in childhood. Acta Neurochir 1979;50(1–2):127–138.

    Article  CAS  Google Scholar 

  99. Evans AE, Jenkin RD, Sposto R, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990;72(4):572–582.

    Article  PubMed  CAS  Google Scholar 

  100. Jenkin D, Goddard K, Armstrong D, et al. Posterior fossa medulloblastoma in childhood: treatment results and a proposal for a new staging system. Int J Radiat Oncol Biol Phys 1990;19(2):265–274.

    PubMed  CAS  Google Scholar 

  101. Cervoni L, Cantore G. Medulloblastoma in pediatric age: a single-institution review of prognostic factors. Childs Nerv Syst 1995;11(2):80–84; discussion 5.

    Article  PubMed  CAS  Google Scholar 

  102. Bouffet E, Bernard JL, Frappaz D, et al. M4 protocol for cerebellar medulloblastoma: supratentorial radiotherapy may not be avoided. Int J Radiat Oncol Biol Phys 1992;24(1):79–85.

    PubMed  CAS  Google Scholar 

  103. Thomas PR, Deutsch M, Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 2000;18(16):3004–3011.

    PubMed  CAS  Google Scholar 

  104. Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group Study. J Clin Oncol 1999;17(7):2127–2136.

    PubMed  CAS  Google Scholar 

  105. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17(3):832–845.

    PubMed  CAS  Google Scholar 

  106. Kortmann RD, Kuhl J, Timmermann B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT’ 91. Int J Radiat Oncol Biol Phys 2000;46(2):269–279.

    Article  PubMed  CAS  Google Scholar 

  107. Carrie C, Muracciole X, Gomez F, et al. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy and online quality control in standard risk medulloblastoma without chemotherapy, results of the French M-SFOP 98 protocol. Int J Radiat Oncol Biol Phys 2003;57(suppl 2):S195.

    Google Scholar 

  108. Tait DM, Thornton-Jones H, Bloom HJ, Lemerle J, Morris-Jones P. Adjuvant chemotherapy for medulloblastoma: the first multicentre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990;26(4):464–469.

    PubMed  CAS  Google Scholar 

  109. Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 Study. J Clin Oncol 2003;21(8):1581–1591.

    Article  PubMed  CAS  Google Scholar 

  110. Mason WP, Grovas A, Halpern S, et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998;16(1):210–221.

    PubMed  CAS  Google Scholar 

  111. Bailey CC, Gnekow A, Wellek S, et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical & Pediatric Oncology 1995;25(3):166–178.

    Article  CAS  Google Scholar 

  112. Hartsell WF, Gajjar A, Heideman RL, et al. Patterns of failure in children with medulloblastoma: effects of preirradiation chemotherapy. Int J Radiat Oncol Biol Phys 1997;39(1):15–24.

    Article  PubMed  CAS  Google Scholar 

  113. Graham ML, Herndon JE II, Casey JR, et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997;15(5):1814–1823.

    PubMed  CAS  Google Scholar 

  114. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer (Phila) 2002;95(7):1504–1510.

    Article  PubMed  Google Scholar 

  115. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992;23(1):9–17.

    PubMed  CAS  Google Scholar 

  116. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998;16(3):859–863.

    PubMed  CAS  Google Scholar 

  117. Bessell EM, Graus F, Punt JA, et al. Primary non-Hodgkin’s lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. J Clin Oncol 1996;14(3):945–954.

    PubMed  CAS  Google Scholar 

  118. DeAngelis LM. Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy. J Neuro-Oncol 1999;43(3):249–257.

    Article  CAS  Google Scholar 

  119. Schlegel U, Pels H, Glasmacher A, et al. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatry 2001;71(1):118–122.

    Article  PubMed  CAS  Google Scholar 

  120. Freilich RJ, Delattre JY, Monjour A, DeAngelis LM. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 1996;46(2):435–439.

    PubMed  CAS  Google Scholar 

  121. Maher EA, Fine HA. Primary CNS lymphoma. Semin Oncol 1999;26(3):346–356.

    PubMed  CAS  Google Scholar 

  122. Ferreri AJ, Reni M, Villa E. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 2000;11(8):927–937.

    Article  PubMed  CAS  Google Scholar 

  123. Shapiro WR, Green SB, Burger PC, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992;76(5):772–781.

    PubMed  CAS  Google Scholar 

  124. Newton HB, Page MA, Junck L, Greenberg HS. Intra-arterial cis-platin for the treatment of malignant gliomas. J Neuro-Oncol 1989;7(1):39–45.

    Article  CAS  Google Scholar 

  125. Mortimer JE, Crowley J, Eyre H, Weiden P, Eltringham J, Stuckey WJ. A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors. A Southwest Oncology Group study. Cancer (Phila) 1992;69(5):1220–1223.

    Article  PubMed  CAS  Google Scholar 

  126. Hiesiger EM, Green SB, Shapiro WR, et al. Results of a randomized trial comparing intra-arterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group trial 8420A. J Neuro-Oncol 1995;25(2):143–154.

    Article  CAS  Google Scholar 

  127. Neuwelt EA, Howieson J, Frenkel EP, et al. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 1986;19(4):573–582.

    Article  PubMed  CAS  Google Scholar 

  128. Zunkeler B, Carson RE, Olson J, et al. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg 1996;85(6):1056–1065.

    Article  PubMed  CAS  Google Scholar 

  129. Schneider T, Gerhards R, Kirches E, Firsching R. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neuro-Oncol 2001;53(1):39–46.

    Article  CAS  Google Scholar 

  130. Cokgor I, Akabani G, Kuan CT, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 2000;18(22):3862–3872.

    PubMed  CAS  Google Scholar 

  131. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002;20(5):1389–1397.

    Article  PubMed  CAS  Google Scholar 

  132. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 2001;50(7):337–344.

    Article  PubMed  CAS  Google Scholar 

  133. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001;61(3):842–847.

    PubMed  CAS  Google Scholar 

  134. Becker R, Eichler MK, Jennemann R, Bertalanffy H. Phase I clinical trial on adjuvant active immunotherapy of human gliomas with GD2-conjugate. Br J Neurosurg 2002;16(3):269–275.

    Article  PubMed  CAS  Google Scholar 

  135. Dunn IF, Black PM. The neurosurgeon as local oncologist: cellular and molecular neurosurgery in malignant glioma therapy. Neurosurgery 2003;52(6):1411–1422; discussion 22–24.

    Article  PubMed  Google Scholar 

  136. Prados MD, McDermott M, Chang SM, et al. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial. J Neuro-Oncol 2003;65(3):269–278.

    Article  Google Scholar 

  137. Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000;11(16):2197–2205.

    Article  PubMed  CAS  Google Scholar 

  138. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000;11(17):2389–2401.

    Article  PubMed  CAS  Google Scholar 

  139. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003;21(13):2508–2518.

    Article  PubMed  CAS  Google Scholar 

  140. Miller CR, Buchsbaum DJ, Reynolds PN, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998;58(24):5738–5748.

    PubMed  CAS  Google Scholar 

  141. Galanis E, Buckner J, Maurer M, et al. NCCTG Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2004;23:107.

    Google Scholar 

  142. Raizer JJ, Abrey LE, Wen P, et al. A phase II trial of elotinib (OSI-774) in patients with recurrent malignant gliomas not on EIAEDs. Proc Am Soc Clin Oncol 2004;23:107 (abstract 1502).

    Google Scholar 

  143. Prados M, Chang S, Burton E, et al. Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. Proc Am Soc Clin Oncol 2003;22(2003):99 (abstract 394).

    Google Scholar 

  144. Raymond E, Brandes A, Van Oosterom A, et al. Multicentre Phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC NDDG/BTG intergroup Study. Proc Am Soc Clin Oncol 2004;23:107 (abstract 1505).

    Google Scholar 

  145. Scott C, Curran WJ, Yung WK, et al. Long term results of RTOG 9006: a randomized trial of hyperfractionated radiotherapy (RT) to 72.0 Gy and carmustine vs. standard RT and carmustine for malignant glioma patients with emphasis on anaplastic astrocytoma (AA) patients. Proc Am Soc Clin Oncol 1998;17:401 (abstract 1546).

    Google Scholar 

  146. Prados MD, Wara WM, Sneed PK, et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001;49(1):71–77.

    Article  PubMed  CAS  Google Scholar 

  147. Laperriere NJ, Leung PM, McKenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998;41(5):1005–1011.

    Article  PubMed  CAS  Google Scholar 

  148. Selker RG, Shapiro WR, Burger P, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 2002;51(2):343–355; discussion 55–57.

    Article  PubMed  Google Scholar 

  149. Souhami L, Scott C, Brachman D, et al. Randomized prospective comparison of stereotactic radiosurgery (SRS) followed by conventional radiotherapy (RT) with BCNU to RT with BCNU alone for selected patients with supratentorial glioblastoma multiforme (GBM): report of RTOG 93-05 protocol. Int J Radiat Oncol Biol Phys 2002;54(2S):94–95 (abstract 158).

    Article  Google Scholar 

  150. Griffin TW, Davis R, Laramore G, et al. Fast neutron radiation therapy for glioblastoma multiforme. Results of an RTOG study. Am J Clin Oncol 1983;6(6):661–667.

    PubMed  CAS  Google Scholar 

  151. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49(3):333–343.

    PubMed  CAS  Google Scholar 

  152. Green SB, Byar DP, Walker MD, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983;67(2):121–132.

    PubMed  CAS  Google Scholar 

  153. Deutsch M, Green SB, Strike TA, et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 1989;16(6):1389–1396.

    PubMed  CAS  Google Scholar 

  154. Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer (Phila) 1983;52(6):997–1007.

    Article  PubMed  CAS  Google Scholar 

  155. Schold SC Jr, Herndon JE, Burger PC, et al. Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. J Clin Oncol 1993;11(1):77–83.

    PubMed  Google Scholar 

  156. Dinapoli RP, Brown LD, Arusell RM, et al. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol 1993;11(7):1316–1321.

    PubMed  CAS  Google Scholar 

  157. Grossman SA, O’Neill A, Grunnet M, et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 2003;21(8):1485–1491.

    Article  PubMed  CAS  Google Scholar 

  158. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002;20(9):2267–2276.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Mayo Clinic Foundation, Rochester, MN, USA

    Brad J. Erickson MD (Associate Professor)

  2. Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA

    Ravi D. Rao MBBS (Senior Associate Consultant) & Evanthia Galanis MD (Associate Professor)

  3. Division of Radiation Oncology, Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA

    Paul D. Brown MD (Assistant Professor)

  4. Department of Anatomic Pathology, Mayo Clinic Foundation, Rochester, MN, USA

    Caterina Giannini MD (Consultant)

  5. Department of Neurosurgery, Mayo Clinic College of Medicine, Rochester, MN, USA

    Cormac O. Maher MD (Chief Resident Associate) & Fredric B. Meyer MD (Professor)

  6. Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA

    Jan C. Buckner MD (Chair and Professor of Oncology)

  7. Mayo Clinic College of Medicine, Rochester, MN, USA

    Jan C. Buckner MD (Chair and Professor of Oncology)

Authors
  1. Ravi D. Rao MBBS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul D. Brown MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Caterina Giannini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cormac O. Maher MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fredric B. Meyer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Evanthia Galanis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Brad J. Erickson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jan C. Buckner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Surgery Oncology, Department of Surgery, University of Michigan, Ann Arbor, MI, USA

    Alfred E. Chang MD (Hugh Cabot Professor of Surgery and Chief) (Hugh Cabot Professor of Surgery and Chief)

  2. Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Daniel F. Hayes MD (Clinical Director) (Clinical Director)

  3. Department of Cardiothoracic Surgery, New York University School of Medicine and Comprehensive Cancer Center, New York, NY, USA

    Harvey I. Pass MD (Professor and Chief of Thoracic Surgery and Head) (Professor and Chief of Thoracic Surgery and Head)

  4. Thoracic Oncology, New York University School of Medicine and Comprehensive Cancer Center, New York, NY, USA

    Harvey I. Pass MD (Professor and Chief of Thoracic Surgery and Head) (Professor and Chief of Thoracic Surgery and Head)

  5. Department of Medicine, Harvard Medical School, USA

    Richard M. Stone MD (Associate Professor and Clinical Director) (Associate Professor and Clinical Director)

  6. Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USA

    Richard M. Stone MD (Associate Professor and Clinical Director) (Associate Professor and Clinical Director)

  7. Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center at UCLA, USA

    Patricia A. Ganz MD (American Cancer Society Clinical Research Professor, Director and Professor) (American Cancer Society Clinical Research Professor, Director and Professor)

  8. Schools of Public Health and Medicine, University of California, Los Angeles, Los Angeles, CA, USA

    Patricia A. Ganz MD (American Cancer Society Clinical Research Professor, Director and Professor) (American Cancer Society Clinical Research Professor, Director and Professor)

  9. Department of Radiation Oncology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

    Timothy J. Kinsella MD (Vincent K. Smith Professor and Chairman) (Vincent K. Smith Professor and Chairman)

  10. Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA

    Joan H. Schiller MD (Melanie Heald Professor of Medical Oncology) (Melanie Heald Professor of Medical Oncology)

  11. Health Media Research Laboratory, Department of Health Behavior and Health Education, University of Michigan School of Public Health, USA

    Victor J. Strecher PhD, MPH (Professor and Director and Associate Director) (Professor and Director and Associate Director)

  12. Cancer Prevention and Control, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Victor J. Strecher PhD, MPH (Professor and Director and Associate Director) (Professor and Director and Associate Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Rao, R.D. et al. (2006). Central Nervous System Tumors. In: Chang, A.E., et al. Oncology. Springer, New York, NY. https://doi.org/10.1007/0-387-31056-8_34

Download citation

  • DOI: https://doi.org/10.1007/0-387-31056-8_34

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-24291-0

  • Online ISBN: 978-0-387-31056-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation